Madhukar Pai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8936893/publications.pdf

Version: 2024-02-01

501 papers	35,632 citations	92 h-index	169 g-index
		3159	4774
518 all docs	518 docs citations	518 times ranked	21287 citing authors

#	Article	IF	Citations
1	Chest X-ray Analysis With Deep Learning-Based Software as a Triage Test for Pulmonary Tuberculosis: An Individual Patient Data Meta-Analysis of Diagnostic Accuracy. Clinical Infectious Diseases, 2022, 74, 1390-1400.	5.8	35
2	Tuberculosis in times of COVID-19. Journal of Epidemiology and Community Health, 2022, 76, 310-316.	3.7	64
3	Simulated patients and their reality: An inquiry into theory and method. Social Science and Medicine, 2022, 300, 114571.	3.8	8
4	Covid-19â€™s Devastating Effect on Tuberculosis Care â€" A Path to Recovery. New England Journal of Medicine, 2022, 386, 1490-1493.	27.0	146
5	Tracking changes in national BCG vaccination policies and practices using the BCG World Atlas. BMJ Global Health, 2022, 7, e007462.	4.7	10
6	Prescribing practices for presumptive TB among private general practitioners in South Africa: a cross-sectional, standardised patient study. BMJ Global Health, 2022, 7, e007456.	4.7	5
7	Integrated testing for TB and COVID-19. Med, 2022, 3, 162-166.	4.4	6
8	Childhood Tuberculosis â€" Time for Shorter and Differentiated Treatment. New England Journal of Medicine, 2022, 386, 988-989.	27.0	4
9	Chapter 4: Diagnosis of tuberculosis infection. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 49-65.	0.5	3
10	The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respiratory Medicine,the, 2022, 10, 603-622.	10.7	99
11	It is not too late to achieve global covid-19 vaccine equity. BMJ, The, 2022, 376, e070650.	6.0	62
12	When it comes to stopping tuberculosis, what is actually â€œmissingâ€?. PLOS Global Public Health, 2022, 2, e0000319.	1.6	3
13	Engaging pharmacies in tuberculosis control: operational lessons from 19 case detection interventions in high-burden countries. BMJ Global Health, 2022, 7, e008661.	4.7	4
14	Most common reasons for primary care visits in low- and middle-income countries: A systematic review. PLOS Global Public Health, 2022, 2, e0000196.	1.6	9
15	Global health education in high-income countries: confronting coloniality and power asymmetry. BMJ Global Health, 2022, 7, e008501.	4.7	22
16	Funders: The missing link in equitable global health research?. PLOS Global Public Health, 2022, 2, e0000583.	1.6	31
17	Bayesian latent class analysis produced diagnostic accuracy estimates that were more interpretable than composite reference standards for extrapulmonary tuberculosis tests. Diagnostic and Prognostic Research, 2022, 6, .	1.8	3
18	How we classify countries and peopleâ€"and why it matters. BMJ Global Health, 2022, 7, e009704.	4.7	62

#	Article	IF	Citations
19	Extrapulmonary Tuberculosis: New Diagnostics and New Policies. The Indian Journal of Chest Diseases & Allied Sciences, 2022, 56, 71-73.	0.1	13
20	Commentary: Lessons from the COVID-19 global health response to inform TB case finding. Healthcare, 2021, 9, 100487.	1.3	8
21	Global tuberculosis awards must do better with equity, diversity, and inclusion. Lancet, The, 2021, 397, 192-193.	13.7	3
22	Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. The Cochrane Library, 2021, 2021, CD009593.	2.8	58
23	Promoting diagnostics as a global good. Nature Medicine, 2021, 27, 367-368.	30.7	11
24	Application of artificial intelligence in digital chest radiography reading for pulmonary tuberculosis screening. Chronic Diseases and Translational Medicine, 2021, 7, 35-40.	1.2	11
25	Undoing supremacy in global health will require more than decolonisation â€“ Authors' reply. Lancet, The, 2021, 397, 1058-1059.	13.7	4
26	Case fatality and recurrent tuberculosis among patients managed in the private sector: A cohort study in Patna, India. PLoS ONE, 2021, 16, e0249225.	2.5	6
27	Can COVID-19 innovations and systems help low- and middle-income countries to re-imagine healthcare delivery?. Med, 2021, 2, 369-373.	4.4	8
28	Using the COVID-19 pandemic to reimagine global health teaching in high-income countries. BMJ Global Health, 2021, 6, e005649.	4.7	21
29	Addressing power asymmetries in global health: Imperatives in the wake of the COVID-19 pandemic. PLoS Medicine, 2021, 18, e1003604.	8.4	127
30	Learning from COVID-19 to reimagine tuberculosis diagnosis. Lancet Microbe, The, 2021, 2, e169-e170.	7.3	32
31	Diagnostic accuracy of point-of-care ultrasound for pulmonary tuberculosis: A systematic review. PLoS ONE, 2021, 16, e0251236.	2.5	18
32	Quality of care for tuberculosis and HIV in the private health sector: a cross-sectional, standardised patient study in South Africa. BMJ Global Health, 2021, 6, e005250.	4.7	15
33	Improving the quality of tuberculosis care in the post-pandemic world. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021, 23, 100212.	1.3	3
34	India's COVID-19 crisis: a call for international action. Lancet, The, 2021, 397, 2132-2135.	13.7	42
35	Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians. Nature Medicine, 2021, 27, 1324-1327.	30.7	12
36	Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis. PLoS Medicine, 2021, 18, e1003682.	8.4	77

#	Article	IF	Citations
37	COVID-19 boosters in rich nations will delay vaccines for all. Nature Medicine, 2021, 27, 1659-1660.	30.7	17
38	Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): A randomised trial and cost-effectiveness analysis. PLoS Medicine, 2021, 18, e1003752.	8.4	25
39	One year of COVID-19 and its impact on private provider engagement for TB: A rapid assessment of intermediary NGOs in seven high TB burden countries. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021, 25, 100277.	1.3	13
40	Asia emerges as a hotbed of diagnostic innovations for tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021, 25, 100267.	1.3	1
41	Availability of essential diagnostics at primary care public clinics in Peru. Microbes and Infection, 2021, 23, 104761.	1.9	8
42	Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis. European Respiratory Journal, 2021, 57, 2000747.	6.7	16
43	The Lancet Commission on diagnostics: transforming access to diagnostics. Lancet, The, 2021, 398, 1997-2050.	13.7	149
44	PLOS Global Public Health, charting a new path towards equity, diversity and inclusion in global health. PLOS Global Public Health, 2021, 1, e0000038.	1.6	7
45	TB case fatality and recurrence in a private sector cohort in Mumbai, India. International Journal of Tuberculosis and Lung Disease, 2021, 25, 738-746.	1.2	2
46	Vax the world. Science, 2021, 374, 1031-1031.	12.6	10
47	Differential yield of universal versus selective drug susceptibility testing of patients with tuberculosis in high-burden countries: a systematic review and meta-analysis. BMJ Global Health, 2020, 5, e003438.	4.7	8
48	Will global health survive its decolonisation?. Lancet, The, 2020, 396, 1627-1628.	13.7	187
49	Indiaâ€™s syndemic of tuberculosis and COVID-19. BMJ Global Health, 2020, 5, e003979.	4.7	42
50	Advances in Molecular Diagnosis of Tuberculosis. Journal of Clinical Microbiology, 2020, 58, .	3.9	83
51	Covidization of research: what are the risks?. Nature Medicine, 2020, 26, 1159-1159.	30.7	47
52	Quality of tuberculosis care in the private health sector. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 20, 100171.	1.3	32
53	A three-marker protein biosignature distinguishes tuberculosis from other respiratory diseases in Gambian children. EBioMedicine, 2020, 58, 102909.	6.1	18
54	Missing men with tuberculosis: the need to address structural influences and implement targeted and multidimensional interventions. BMJ Global Health, 2020, 5, e002255.	4.7	34

#	Article	IF	Citations
55	Global health degrees: at what cost?. BMJ Global Health, 2020, 5, e003310.	4.7	31
56	Antibiotic overuse in the primary health care setting: a secondary data analysis of standardised patient studies from India, China and Kenya. BMJ Global Health, 2020, 5, e003393.	4.7	63
57	SARS-CoV-2 testing in low- and middle-income countries: availability and affordability in the private health sector. Microbes and Infection, 2020, 22, 511-514.	1.9	10
58	How are high burden countries implementing policies and tools for latent tuberculosis infection? A survey of current practices and barriers. Health Science Reports, 2020, 3, e158.	1.5	23
59	COVID-19 and tuberculosis in South Africa: A dangerous combination. South African Medical Journal, 2020, 110, 341.	0.6	24
60	Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?. Journal of Clinical Microbiology, 2020, 58, .	3.9	55
61	Antibiotic prescription practices in primary care in low- and middle-income countries: A systematic review and meta-analysis. PLoS Medicine, 2020, 17, e1003139.	8.4	130
62	An appeal for practical social justice in the COVID-19 global response in low-income and middle-income countries. The Lancet Global Health, 2020, 8, e888-e889.	6.3	69
63	User experience and patient satisfaction with tuberculosis care in low- and middle-income countries: A systematic review. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 19, 100154.	1.3	16
64	Deep learning, computer-aided radiography reading for tuberculosis: a diagnostic accuracy study from a tertiary hospital in India. Scientific Reports, 2020, 10, 210.	3.3	56
65	Isoniazid-resistant tuberculosis: A problem we can no longer ignore. PLoS Medicine, 2020, 17, e1003023.	8.4	35
66	Tuberculosis: the story after the Primer. Nature Reviews Disease Primers, 2020, 6, 29.	30.5	7
67	Tuberculosis case fatality in India: a systematic review and meta-analysis. BMJ Global Health, 2020, 5, e002080.	4.7	24
68	Finding the missing millions: lessons from 10 active case finding interventions in high tuberculosis burden countries. BMJ Global Health, 2020, 5, e003835.	4.7	19
69	Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers. Gates Open Research, 2020, 4, 24.	1.1	33
70	Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers. Gates Open Research, 2020, 4, 24.	1.1	25
71	Title is missing!. , 2020, 17, e1003139.		0
72	Title is missing!. , 2020, 17, e1003139.		0

#	Article	IF	Citations
73	Title is missing!. , 2020, 17, e1003139.		0
74	Title is missing!. , 2020, 17, e1003139.		0
75	Title is missing!. , 2020, 17, e1003139.		0
76	Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model. BMC Medicine, 2019, 17, 155.	5.5	19
77	Tackling drug-resistant tuberculosis: we need a critical synergy of product and process innovations. International Journal of Tuberculosis and Lung Disease, 2019, 23, 774-782.	1.2	5
78	Lessons on the quality of tuberculosis diagnosis from standardized patients in China, India, Kenya, and South Africa. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 16, 100109.	1.3	35
79	A roadmap to engage all care providers in tuberculosis prevention and care. International Journal of Tuberculosis and Lung Disease, 2019, 23, 641-642.	1.2	0
80	Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. Journal of Infectious Diseases, 2019, 220, S99-S107.	4.0	19
81	Guidance for the Evaluation of Tuberculosis Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles. Journal of Infectious Diseases, 2019, 220, S91-S98.	4.0	17
82	Improving the cascade of global tuberculosis care: moving from the â€œwhatâ€•to the â€œhowâ€•of quality improvement. Lancet Infectious Diseases, The, 2019, 19, e437-e443.	9.1	22
83	Essential medicines and essential diagnostics: a package deal. Lancet Public Health, The, 2019, 4, e492.	10.0	14
84	A systematic review of the diagnostic accuracy of artificial intelligence-based computer programs to analyze chest x-rays for pulmonary tuberculosis. PLoS ONE, 2019, 14, e0221339.	2.5	113
85	What will it take to eliminate drug-resistant tuberculosis?. International Journal of Tuberculosis and Lung Disease, 2019, 23, 535-546.	1.2	18
86	Can community pharmacists improve tuberculosis case finding? A mixed methods intervention study in India. BMJ Global Health, 2019, 4, e001417.	4.7	30
87	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	13.7	257
88	Tuberculosis. Lancet, The, 2019, 393, 1642-1656.	13.7	523
89	Constructing care cascades for active tuberculosis: A strategy for program monitoring and identifying gaps in quality of care. PLoS Medicine, 2019, 16, e1002754.	8.4	120
90	Health care gaps in the global burden of drug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2019, 23, 125-135.	1.2	14

#	Article	IF	Citations
91	Use of standardised patients to assess gender differences in quality of tuberculosis care in urban India: a two-city, cross-sectional study. The Lancet Global Health, 2019, 7, e633-e643.	6.3	22
92	Diagnostic Accuracy of Stool Xpert MTB/RIF for Detection of Pulmonary Tuberculosis in Children: a Systematic Review and Meta-analysis. Journal of Clinical Microbiology, 2019, 57, .	3.9	64
93	Tuberculosis: treatment failure, or failure to treat? Lessons from India and South Africa. BMJ Global Health, 2019, 4, e001097.	4.7	34
94	A systematic review of biomarkers to detect active tuberculosis. Nature Microbiology, 2019, 4, 748-758.	13.3	146
95	Use of standardised patients for healthcare quality research in low- and middle-income countries. BMJ Global Health, 2019, 4, e001669.	4.7	66
96	Global health journals need to address equity, diversity and inclusion. BMJ Global Health, 2019, 4, e002018.	4.7	51
97	Why we need to evaluate the quality of tuberculosis care in South Africaâ€™s private health sector. South African Medical Journal, 2019, 109, 817.	0.6	2
98	Self-reported tuberculosis in India: evidence from NFHS-4. BMJ Global Health, 2019, 4, e001371.	4.7	23
99	Over-the-counter antibiotic dispensing by pharmacies: a standardised patient study in Udupi district, India. BMJ Global Health, 2019, 4, e001869.	4.7	25
100	Initiative for Promoting Affordable and Quality Tuberculosis Tests (IPAQT): a market-shaping intervention in India. BMJ Global Health, 2019, 4, e001539.	4.7	12
101	Improving access to essential tests for infectious diseases. Microbes and Infection, 2019, 21, 1-3.	1.9	2
102	Diagnosing active tuberculosis in people living with HIV. Current Opinion in HIV and AIDS, 2019, 14, 46-54.	3.8	11
103	Quality: The missing ingredient in TB care and control. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 14, 12-13.	1.3	21
104	Higher Positivity Rate with Fourth-Generation QuantiFERON-TB Gold Plus Assay in Low-Risk U.S. Health Care Workers. Journal of Clinical Microbiology, 2019, 57, .	3.9	6
105	Industry Perspectives on the WHO Essential Diagnostics List. Journal of Clinical Microbiology, 2019, 57, .	3.9	2
106	Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Library, 2019, 6, CD009593.	2.8	144
107	Drug-resistant tuberculosis: Progress towards shorter and safer regimens. Lung India, 2019, 36, 373.	0.7	4
108	Implementation of Xpert^{Â®} MTB/RIF in high-burden countries: voices from the field matter. Public Health Action, 2019, 9, 78-79.	1.2	2

#	Article	IF	Citations
109	A universal manuscript for all medical journals. The National Medical Journal of India, 2019, 32, 254.	0.3	1
110	Urine Lipoarabinomannan for Tuberculosis Diagnosis: Evolution and Prospects. Clinical Chemistry, 2018, 64, 1133-1135.	3.2	7
111	Performance of the Xpert HIV-1 Viral Load Assay: a Systematic Review and Meta-analysis. Journal of Clinical Microbiology, 2018, 56, .	3.9	34
112	Tuberculosis: a Persistent Health Challenge for India. Current Epidemiology Reports, 2018, 5, 18-23.	2.4	4
113	Quality of tuberculosis care by Indian pharmacies: Mystery clients offer new insights. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2018, 10, 6-8.	1.3	8
114	Surrogate endpoints in global health research: still searching for killer apps and silver bullets?. BMJ Global Health, 2018, 3, e000755.	4.7	44
115	Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: A trend analysis from 2014 - 2016. Gates Open Research, 2018, 2, 35.	1.1	54
116	The WHO list of essential in vitro diagnostics: Development and next steps. EBioMedicine, 2018, 37, 1-2.	6.1	7
117	Variations in the quality of tuberculosis care in urban India: A cross-sectional, standardized patient study in two cities. PLoS Medicine, 2018, 15, e1002653.	8.4	97
118	Availability of essential diagnostics in primary care in India. Lancet Infectious Diseases, The, 2018, 18, 1064-1065.	9.1	17
119	Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities. BMJ Global Health, 2018, 3, e001018.	4.7	166
120	Knowledge about tuberculosis and infection prevention behavior: A nine city longitudinal study from India. PLoS ONE, 2018, 13, e0206245.	2.5	22
121	Biomarkers for diagnosis of childhood tuberculosis: A systematic review. PLoS ONE, 2018, 13, e0204029.	2.5	42
122	A bibliometric analysis of tuberculosis research, 2007â€“2016. PLoS ONE, 2018, 13, e0199706.	2.5	64
123	A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 2695-2702.	2.3	5
124	La tuberculose durant la grossesse: une menace trop souvent nÃ©gligÃ©e. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 1006-1008.	0.7	1
125	Prevalence of diabetes mellitus amongst hospitalized tuberculosis patients at an Indian tertiary care center: A descriptive analysis. PLoS ONE, 2018, 13, e0200838.	2.5	31
126	New strategies for inpatients with HIV and tuberculosis. Lancet, The, 2018, 392, 256-258.	13.7	2

#	Article	IF	Citations
127	New TB Tools Need to be Affordable in the Private Sector: The Case Study of Xpert MTB/RIF. Journal of Epidemiology and Global Health, 2018, 8, 103.	2.9	6
128	Tuberculosis in Pregnancy: A Treacherous Yet Neglected Issue. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 1003-1005.	0.7	10
129	A List To Cement the Rightful Place of Diagnostics in Health Care. Journal of Clinical Microbiology, 2018, 56, .	3.9	5
130	Impact of nicotine replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised controlled trial. Scientific Reports, 2018, 8, 8828.	3.3	13
131	Time for high-burden countries to lead the tuberculosis research agenda. PLoS Medicine, 2018, 15, e1002544.	8.4	11
132	Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: A trend analysis from 2014 - 2016. Gates Open Research, 2018, 2, 35.	1.1	38
133	Design and protocol for a pragmatic randomised study to optimise screening, prevention and care for tuberculosis and HIV in Malawi (PROSPECT Study). Wellcome Open Research, 2018, 3, 61.	1.8	9
134	New TB Tools Need to be Affordable in the Private Sector: The Case Study of Xpert MTB/RIF. Journal of Epidemiology and Global Health, 2018, 8, 103.	2.9	10
135	Ending tuberculosis in India: A political challenge & an opportunity. Indian Journal of Medical Research, 2018, 147, 217.	1.0	10
136	Barriers to Point of Care Testing in India and South Africa. , 2018, , 75-85.		0
137	Design and protocol for a pragmatic randomised study to optimise screening, prevention and care for tuberculosis and HIV in Malawi (PROSPECT Study). Wellcome Open Research, 2018, 3, 61.	1.8	5
138	Mind the gap: Time to address implementation gaps in tuberculosis diagnosis and treatment. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2017, 6, 14-15.	1.3	5
139	Enhancing the role of pharmacists in the cascade of tuberculosis care. Journal of Epidemiology and Global Health, 2017, 7, 1.	2.9	20
140	Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. European Respiratory Journal, 2017, 49, 1601075.	6.7	100
141	Impact of fluoroquinolone treatment on delay of tuberculosis diagnosis: A systematic review and meta-analysis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2017, 6, 1-7.	1.3	17
142	The uncertain science of predicting tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 239-240.	10.7	3
143	A tuberculosis biomarker database: the key to novel TB diagnostics. International Journal of Infectious Diseases, 2017, 56, 253-257.	3.3	44
144	India's plan to eliminate tuberculosis by 2025: converting rhetoric into reality. BMJ Global Health, 2017, 2, e000326.	4.7	32

#	Article	IF	Citations
145	New tuberculosis estimates must motivate countries to act. Journal of Epidemiology and Global Health, 2017, 7, 97.	2.9	1
146	Reducing global tuberculosis deathsâ€"time for India to step up. Lancet, The, 2017, 389, 1174-1176.	13.7	22
147	Real-Time Sequencing of Mycobacterium tuberculosis: Are We There Yet?. Journal of Clinical Microbiology, 2017, 55, 1249-1254.	3.9	38
148	Evaluation of QuantiFERON-TB Gold-Plus in Health Care Workers in a Low-Incidence Setting. Journal of Clinical Microbiology, 2017, 55, 1650-1657.	3.9	50
149	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases, 2017, 64, e1-e33.	5.8	501
150	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases, 2017, 64, 111-115.	5.8	492
151	Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2017, 49, 1600993.	6.7	20
152	Countries need to step up to end tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2017, 8, 33-34.	1.3	0
153	A 360-degree view of an ancient killer disease. Journal of Epidemiology and Global Health, 2017, 7, 209.	2.9	0
154	Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?. European Respiratory Journal, 2017, 50, 1700918.	6.7	35
155	Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy. European Respiratory Journal, 2017, 50, 1700953.	6.7	40
156	Use of the GeneXpert tuberculosis system for HIV viral load testing in India. The Lancet Global Health, 2017, 5, e754-e755.	6.3	20
157	Detecting New Mycobacterium tuberculosis Infection. Time for a More Nuanced Interpretation of QuantiFERON Conversions. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 546-547.	5.6	11
158	How patients navigate the diagnostic ecosystem in a fragmented health system: a qualitative study from India. Global Health Action, 2017, 10, 1350452.	1.9	34
159	Fighting TB stigma: we need to apply lessons learnt from HIV activism. BMJ Global Health, 2017, 2, e000515.	4.7	51
160	Tuberculosis in India: health policy alone is not enough â€" Authors' reply. Lancet, The, 2017, 389, 2471-2472.	13.7	2
161	Taking Costs and Diagnostic Test Accuracy into Account When Designing Prevalence Studies: An Application to Childhood Tuberculosis Prevalence. Medical Decision Making, 2017, 37, 922-929.	2.4	1
162	Making HIV testing work at the point of care in South Africa: a qualitative study of diagnostic practices. BMC Health Services Research, 2017, 17, 408.	2.2	19

#	Article	IF	Citations
163	Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. International Journal of Infectious Diseases, 2017, 56, 111-116.	3.3	136
164	Molecular diagnosis of tuberculosis: we need solutions that span the healthcare value chain. Expert Review of Molecular Diagnostics, 2017, 17, 5-7.	3.1	6
165	Tuberculosis detection and the cost of integrated care in rural China: a cross-sectional standardised patient study. Lancet, The, 2017, 390, S60.	13.7	0
166	Enhancing quality of medical care in low income and middle income countries through simulation-based initiatives: recommendations of the Simnovate Global Health Domain Group. BMJ Simulation and Technology Enhanced Learning, 2017, 3, S15-S22.	0.7	20
167	Exploring the epidemiological impact of universal access to rapid tuberculosis diagnosis using agent-based simulation. , 2017, , .		2
168	Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. , 2017, , 379-388.		0
169	Do rats pass the sniff test?. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1089-1090.	1.2	1
170	Tuberculosis detection and the challenges of integrated care in rural China: A cross-sectional standardized patient study. PLoS Medicine, 2017, 14, e1002405.	8.4	93
171	Missing tuberculosis patients in the private sector: business as usual will not deliver results. Public Health Action, 2017, 7, 80-81.	1.2	9
172	In reply. International Journal of Tuberculosis and Lung Disease, 2017, 21, 472-473.	1.2	0
173	Diagnosis of Childhood Tuberculosis. , 2017, , .		3
174	Evaluating cliniciansâ€™ user experience and acceptability of LearnTB, a smartphone application for tuberculosis in India. MHealth, 2017, 3, 30-30.	1.6	14
175	Tuberculosis innovations mean little if they cannot save lives. ELife, 2017, 6, .	6.0	39
176	Implementation of the Xpert MTB/RIF assay for tuberculosis in Mongolia: a qualitative exploration of barriers and enablers. PeerJ, 2017, 5, e3567.	2.0	15
177	Diagnosis of Tuberculosis: Current Pipeline, Unmet Needs, and New Developments. , 2017, , 77-98.		0
178	India's fight against tuberculosis: How can chest physicians help?. Lung India, 2017, 34, 120.	0.7	3
179	Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination. International Journal of Tuberculosis and Lung Disease, 2016, 20, 999-1003.	1.2	26
180	Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLoS ONE, 2016, 11, e0151724.	2.5	12

#	Article	IF	Citations
181	Tuberculosis Diagnostics: State of the Art and Future Directions. Microbiology Spectrum, 2016, 4, .	3.0	87
182	Addressing the challenges of diagnostics demand and supply: insights from an online global health discussion platform. BMJ Global Health, 2016, 1, e000132.	4.7	53
183	Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. Microbiology Spectrum, 2016, 4, .	3.0	71
184	Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults. BMJ Global Health, 2016, 1, e000064.	4.7	7
185	Market assessment of tuberculosis diagnostics in China in 2012. International Journal of Tuberculosis and Lung Disease, 2016, 20, 295-303.	1.2	6
186	Market assessment of tuberculosis diagnostics in India in 2013. International Journal of Tuberculosis and Lung Disease, 2016, 20, 304-313.	1.2	6
187	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. European Respiratory Journal, 2016, 48, 1160-1170.	6.7	27
188	Use of standardised patients to assess antibiotic dispensing for tuberculosis by pharmacies in urban India: a cross-sectional study. Lancet Infectious Diseases, The, 2016, 16, 1261-1268.	9.1	94
189	Computer-aided detection of pulmonary tuberculosis on digital chest radiographs: a systematic review. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1226-1230.	1.2	92
190	Engaging health-care workers to reduce tuberculosis transmission. Lancet Infectious Diseases, The, 2016, 16, 883-885.	9.1	6
191	Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?. European Respiratory Journal, 2016, 48, 516-525.	6.7	239
192	Location, location, location: tuberculosis services in highest burden countries. The Lancet Global Health, 2016, 4, e907-e908.	6.3	24
193	Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model. Scientific Reports, 2016, 6, 30781.	3.3	27
194	Tuberculosis. Nature Reviews Disease Primers, 2016, 2, 16076.	30.5	830
195	Diagnostic Test Accuracy in Childhood Pulmonary Tuberculosis: A Bayesian Latent Class Analysis. American Journal of Epidemiology, 2016, 184, 690-700.	3.4	52
196	How do patients access the private sector in Chennai, India? An evaluation of delays in tuberculosis diagnosis. International Journal of Tuberculosis and Lung Disease, 2016, 20, 544-551.	1.2	27
197	Interferon Gamma Release Assays for Latent Tuberculosis: What Are the Sources of Variability?. Journal of Clinical Microbiology, 2016, 54, 845-850.	3.9	83
198	Treatment as diagnosis and diagnosis as treatment: empirical management of presumptive tuberculosis in India. International Journal of Tuberculosis and Lung Disease, 2016, 20, 536-543.	1.2	54

#	Article	IF	Citations
199	Xpert MTB/RIF for tuberculosis testing: access and price in highly privatised health markets. The Lancet Global Health, 2016, 4, e94-e95.	6.3	27
200	TB control: challenges and opportunities for India. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 158-160.	1.8	25
201	Alternative medicine: an ethnographic study of how practitioners of Indian medical systems manage TB in Mumbai. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 192-198.	1.8	15
202	Antimicrobial resistance and the growing threat of drug-resistant tuberculosis. Journal of Epidemiology and Global Health, 2016, 6, 45.	2.9	7
203	Assessing the quality of tuberculosis care in India â€“ Authors' response. Lancet Infectious Diseases, The, 2016, 16, 22.	9.1	0
204	Diagnostics for latent TB infection: incremental, not transformative progress. European Respiratory Journal, 2016, 47, 704-706.	6.7	31
205	The Tuberculosis Cascade of Care in Indiaâ€™s Public Sector: A Systematic Review and Meta-analysis. PLoS Medicine, 2016, 13, e1002149.	8.4	195
206	How Do Urban Indian Private Practitioners Diagnose and Treat Tuberculosis? A Cross-Sectional Study in Chennai. PLoS ONE, 2016, 11, e0149862.	2.5	17
207	XpertÂ®MTB/RIF for the Diagnosis of Tuberculosis in a Remote Arctic Setting: Impact on Cost and Time to Treatment Initiation. PLoS ONE, 2016, 11, e0150119.	2.5	10
208	Impact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study Methodologies. PLoS ONE, 2016, 11, e0151073.	2.5	37
209	Tuberculosis therapy in Mumbai: Critical importance of drug-susceptibility testing. Lung India, 2016, 33, 251.	0.7	6
210	Use of Rapid, Point-of-Care Assays by Private Practitioners in Chennai, India: Priorities for Tuberculosis Diagnostic Testing. PLoS ONE, 2016, 11, e0155775.	2.5	1
211	Computer Aided Diagnosis of Tuberculosis Using Digital Chest Radiographs: A Systematic Review. Chest, 2015, 148, 135A.	0.8	2
212	Quality of tuberculosis care in India: a systematic review. International Journal of Tuberculosis and Lung Disease, 2015, 19, 751-763.	1.2	106
213	A killer combination that must be stopped. International Journal of Tuberculosis and Lung Disease, 2015, 19, 877-878.	1.2	1
214	Point-of-care testing in India: missed opportunities to realize the true potential of point-of-care testing programs. BMC Health Services Research, 2015, 15, 550.	2.2	24
215	Use of Chest X-rays in 22 High Tuberculosis Burden Countries. Chest, 2015, 148, 141A.	0.8	1
216	Point-of-Care Diagnostic Testing in Global Health: What Is the Point?. Microbe Magazine, 2015, 10, 103-107.	0.4	26

#	Article	IF	Citations
217	Achieving Systemic and Scalable Private Sector Engagement in Tuberculosis Care and Prevention in Asia. PLoS Medicine, 2015, 12, e1001842.	8.4	64
218	Barriers to Point-of-Care Testing in India: Results from Qualitative Research across Different Settings, Users and Major Diseases. PLoS ONE, 2015, 10, e0135112.	2.5	47
219	The Feasibility, Accuracy, and Impact of Xpert MTB/RIF Testing in a Remote Aboriginal Community in Canada. Chest, 2015, 148, 767-773.	0.8	10
220	Impact of point-of-care implementation of Xpert^{Â®} MTB/RIF: product vs. process innovation. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1084-1090.	1.2	13
221	Market assessment of tuberculosis diagnostics in South Africa, 2012â€“2013. International Journal of Tuberculosis and Lung Disease, 2015, 19, 216-222.	1.2	20
222	Global tuberculosis control requires greater ambition and resources. Journal of Epidemiology and Global Health, 2015, 5, 1.	2.9	5
223	How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?. European Respiratory Journal, 2015, 45, 549-554.	6.7	52
224	Management of latent tuberculosis infection: An evidence-based approach. Lung India, 2015, 32, 205.	0.7	37
225	Target Product Profile of a Molecular Drug-Susceptibility Test for Use in Microscopy Centers. Journal of Infectious Diseases, 2015, 211, S39-S49.	4.0	36
226	Defining the Needs for Next Generation Assays for Tuberculosis. Journal of Infectious Diseases, 2015, 211, S29-S38.	4.0	133
227	Testing and Treating the Missing Millions with Tuberculosis. PLoS Medicine, 2015, 12, e1001805.	8.4	34
228	Innovations in Tuberculosis Diagnostics: Progress and Translational Challenges. EBioMedicine, 2015, 2, 182-183.	6.1	24
229	TB control requires new tools, policies, and delivery models. Indian Journal of Tuberculosis, 2015, 62, 1-3.	0.7	3
230	Tuberculosis Diagnostics in 2015: Landscape, Priorities, Needs, and Prospects. Journal of Infectious Diseases, 2015, 211, S21-S28.	4.0	166
231	Advances in Tuberculosis Diagnostics. Current Tropical Medicine Reports, 2015, 2, 54-61.	3.7	8
232	Potential Market for Novel Tuberculosis Diagnostics: Worth the Investment?. Journal of Infectious Diseases, 2015, 211, S58-S66.	4.0	11
233	Compounding diagnostic delays: a qualitative study of pointâ€ofâ€care testing in <scp>S</scp>outh <scp>A</scp>frica. Tropical Medicine and International Health, 2015, 20, 493-500.	2.3	30
234	Use of chest radiography in the 22 highest tuberculosis burden countries. European Respiratory Journal, 2015, 46, 1816-1819.	6.7	39

#	Article	IF	Citations
235	Psychological distress and its relationship with non-adherence to TB treatment: a multicentre study. BMC Infectious Diseases, 2015, 15, 253.	2.9	49
236	Use of standardised patients to assess quality of tuberculosis care: a pilot, cross-sectional study. Lancet Infectious Diseases, The, 2015, 15, 1305-1313.	9.1	186
237	Xpert^{Â®} MTB/RIF for extra-pulmonary tuberculosis: time to look beyond accuracy. International Journal of Tuberculosis and Lung Disease, 2015, 19, 2-2.	1.2	4
238	Costs and Consequences of Using Interferon-Î³ Release Assays for the Diagnosis of Active Tuberculosis in India. PLoS ONE, 2015, 10, e0124525.	2.5	13
239	A Survey on Use of Rapid Tests and Tuberculosis Diagnostic Practices by Primary Health Care Providers in South Africa: Implications for the Development of New Point-of-Care Tests. PLoS ONE, 2015, 10, e0141453.	2.5	14
240	The End TB Strategy : India can blaze the trail. Indian Journal of Medical Research, 2015, 141, 259.	1.0	19
241	Do We Need to Detect Isoniazid Resistance in Addition to Rifampicin Resistance in Diagnostic Tests for Tuberculosis?. PLoS ONE, 2014, 9, e84197.	2.5	26
242	Market Assessment of Tuberculosis Diagnostics in Brazil in 2012. PLoS ONE, 2014, 9, e104105.	2.5	11
243	Reply to El Sahly. Clinical Infectious Diseases, 2014, 59, 912-912.	5.8	0
244	The Importance of Implementation Strategy in Scaling Up Xpert MTB/RIF for Diagnosis of Tuberculosis in the Indian Health-Care System: A Transmission Model. PLoS Medicine, 2014, 11, e1001674.	8.4	42
245	Occupational Screening for Tuberculosis. A Testing Time for Interferon-Î³ Release Assays. Annals of the American Thoracic Society, 2014, 11, 399-401.	3.2	6
246	Serial testing using interferon-Â release assays in nursing students in India. European Respiratory Journal, 2014, 44, 257-260.	6.7	7
247	Interferon Î³â€“Release Assays for Diagnosis of Latent Tuberculosis in Healthcare Workers in Low-Incidence Settings: Pros and Cons. Clinical Chemistry, 2014, 60, 714-718.	3.2	5
248	Interpretation of Alvin Coburn's The Bridge, Venice in Pen and Ink. Clinical Chemistry, 2014, 60, 798-799.	3.2	0
249	Tuberculosis control needs a complete and patient-centric solution. The Lancet Global Health, 2014, 2, e189-e190.	6.3	34
250	Tuberculosis diagnostics: which target product profiles should be prioritised?. European Respiratory Journal, 2014, 44, 537-540.	6.7	67
251	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clinical Microbiology Reviews, 2014, 27, 3-20.	13.6	662
252	Improving the quality of tuberculosis care: We need standards and strategies to translate them into practice. Journal of Epidemiology and Global Health, 2014, 4, 77.	2.9	5

#	Article	IF	Citations
253	Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet, The, 2014, 383, 424-435.	13.7	379
254	Safety of the two-step tuberculin skin test in Indian health care workers. International Journal of Mycobacteriology, 2014, 3, 247-251.	0.6	7
255	Using cerebrospinal fluid for the diagnosis of tuberculous meningitis with GeneXpert. European Respiratory Journal, 2014, 44, 1095-1096.	6.7	8
256	Reproducibility of Interferon Gamma (IFN-Î³) Release Assays. A Systematic Review. Annals of the American Thoracic Society, 2014, 11, 1267-1276.	3.2	85
257	The need to furtheraugment the public health system to control tuberculosis â€“ Authors' reply. The Lancet Global Health, 2014, 2, e389.	6.3	1
258	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1364-1374.	5.8	116
259	A Bayesian framework for estimating the incremental value of a diagnostic test in the absence of a gold standard. BMC Medical Research Methodology, 2014, 14, 67.	3.1	20
260	Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential?. European Respiratory Journal, 2014, 43, 1793-1796.	6.7	53
261	XpertÂ® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Library, 2014, , CD009593.	2.8	660
262	Tuberculosis: progress and challenges in product development and delivery. Lancet Respiratory Medicine,the, 2014, 2, 25-27.	10.7	3
263	Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal, 2014, 44, 435-446.	6.7	413
264	Xpert MTB/RIF Testing in a Low Tuberculosis Incidence, High-Resource Setting: Limitations in Accuracy and Clinical Impact. Clinical Infectious Diseases, 2014, 58, 970-976.	5.8	87
265	Genetically Low Triglycerides and Mortality: Further Support for â€œthe Earlier the Betterâ€?. Clinical Chemistry, 2014, 60, 705-707.	3.2	3
266	Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. International Journal of Tuberculosis and Lung Disease, 2014, 18, 255-266.	1.2	275
267	Use of rapid point-of-care tests by primary health care providers in India: findings from a community-based survey. Public Health Action, 2014, 4, 249-251.	1.2	4
268	Improving quality of tuberculosis care in India. Indian Journal of Tuberculosis, 2014, 61, 12-8.	0.7	2
269	Undernutrition and the incidence of tuberculosis in India: national and subnational estimates of the population-attributable fraction related to undernutrition. The National Medical Journal of India, 2014, 27, 128-33.	0.3	47
270	Tuberculosis vaccine trials. Lancet, The, 2013, 381, 2252-2253.	13.7	3

#	Article	IF	Citations
271	Challenges with QuantiFERON-TB Gold Assay for Large-Scale, Routine Screening of U.S. Healthcare Workers. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1005-1010.	5.6	89
272	Impact of Blood Volume, Tube Shaking, and Incubation Time on Reproducibility of QuantiFERON-TB Gold In-Tube Assay. Journal of Clinical Microbiology, 2013, 51, 3521-3526.	3.9	47
273	XpertÂ® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. , 2013, , CD009593.		283
274	Gamma Interferon Release Assay for Monitoring of Treatment Response for Active Tuberculosis: an Explosion in the Spaghetti Factory. Journal of Clinical Microbiology, 2013, 51, 607-610.	3.9	50
275	New tuberculosis tools are here: Can we deliver them for maximal impact?. Journal of Epidemiology and Global Health, 2013, 3, 1.	2.9	2
276	Tuberculosis diagnostics: Why we need more qualitative research. Journal of Epidemiology and Global Health, 2013, 3, 119.	2.9	17
277	Trajectories of tuberculosis-specific interferon-gamma release assay responses among medical and nursing students in rural India. Journal of Epidemiology and Global Health, 2013, 3, 105.	2.9	14
278	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2013, 42, 169-179.	6.7	226
279	Scoring systems using chest radiographic features for the diagnosis of pulmonary tuberculosis in adults: a systematic review. European Respiratory Journal, 2013, 42, 480-494.	6.7	59
280	Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infectious Diseases, The, 2013, 13, 449-458.	9.1	59
281	Diagnostics for tuberculosis: what test developers want to know. Expert Review of Molecular Diagnostics, 2013, 13, 311-314.	3.1	15
282	Mobile health to improve tuberculosis care and control: a call worth making [Review article]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 719-727.	1.2	67
283	A new resource for TB diagnostics developers. Future Microbiology, 2013, 8, 1507-1509.	2.0	0
284	Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis: Table 1â€“. European Respiratory Journal, 2013, 42, 1427-1429.	6.7	53
285	Incremental value of T-SPOT.TBfor diagnosis of active pulmonary tuberculosis in children in a high-burden setting: a multivariable analysis. Thorax, 2013, 68, 860-866.	5.6	30
286	Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics?. European Respiratory Journal, 2013, 42, 544-547.	6.7	51
287	Occupational screening of health care workers for tuberculosis infection: tuberculin skin testing or interferon-Â release assays?. Occupational Medicine, 2013, 63, 458-460.	1.4	16
288	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. European Respiratory Journal, 2013, 42, 156-168.	6.7	346

#	Article	IF	Citations
289	Modeling the Impact of Alternative Strategies for Rapid Molecular Diagnosis of Tuberculosis in Southeast Asia. American Journal of Epidemiology, 2013, 178, 1740-1749.	3.4	31
290	Promoting Affordable and Quality Tuberculosis Testing in India. Journal of Laboratory Physicians, 2013, 5, 01-04.	1.1	22
291	Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countries. Expert Review of Molecular Diagnostics, 2013, 13, 763-767.	3.1	28
292	Smoking and tuberculous infection: chasing associations with imperfect exposure and outcome measures [Editorial]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1375-1376.	1.2	1
293	Tuberculosis diagnostics: test developers' FAQs [Editorial]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 570-571.	1.2	13
294	Methodological and reporting quality of systematic reviews on tuberculosis. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1160-1169.	1.2	14
295	Evaluation of the Reporting Validity of Central Lineâ€"Associated Bloodstream Infection Data to a Provincial Surveillance Program. Infection Control and Hospital Epidemiology, 2013, 34, 217-219.	1.8	6
296	Nutritional Status of Adult Patients with Pulmonary Tuberculosis in Rural Central India and Its Association with Mortality. PLoS ONE, 2013, 8, e77979.	2.5	128
297	Development of a Simple Reliable Radiographic Scoring System to Aid the Diagnosis of Pulmonary Tuberculosis. PLoS ONE, 2013, 8, e54235.	2.5	34
298	Repeat IGRA Testing in Canadian Health Workers: Conversions or Unexplained Variability?. PLoS ONE, 2013, 8, e54748.	2.5	63
299	Challenges in the Development of an Immunochromatographic Interferon-Gamma Test for Diagnosis of Pleural Tuberculosis. PLoS ONE, 2013, 8, e85447.	2.5	4
300	Management of tuberculosis in India: time for a deeper dive into quality. The National Medical Journal of India, 2013, 26, 65-8.	0.3	8
301	TB diagnostics in India: creating an ecosystem for innovation. Expert Review of Molecular Diagnostics, 2012, 12, 21-24.	3.1	10
302	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	8.4	430
303	Point-of-Care Testing for Infectious Diseases: Diversity, Complexity, and Barriers in Low- And Middle-Income Countries. PLoS Medicine, 2012, 9, e1001306.	8.4	447
304	New tuberculosis technologies: challenges for retooling and scale-up [State of the art series. New tools. Number 4 in the series]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1281-1290.	1.2	23
305	Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. European Respiratory Journal, 2012, 39, 163-171.	6.7	26
306	Microcolony culture techniques for tuberculosis diagnosis: a systematic review [Review article]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 16-23.	1.2	40

#	Article	IF	Citations
307	Can Social Interventions Prevent Tuberculosis?. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 442-449.	5.6	46
308	Widespread use of serological tests for tuberculosis: data from 22 high-burden countries. European Respiratory Journal, 2012, 39, 502-505.	6.7	34
309	Promise versus Reality: Optimism Bias in Package Inserts for Tuberculosis Diagnostics. Journal of Clinical Microbiology, 2012, 50, 2455-2461.	3.9	10
310	Rejoinder. Epidemiology, 2012, 23, 927-928.	2.7	1
311	Bridging the Gap Between Knowledge and Health. Epidemiology, 2012, 23, 914-918.	2.7	9
312	Evaluation of the Impact of Interferon-Gamma Release Assays on the Management of Childhood Tuberculosis. Pediatric Infectious Disease Journal, 2012, 31, 1258-1262.	2.0	13
313	Serial Testing With TB Interferon-Î³ Release Assays. Chest, 2012, 142, 1366-1368.	0.8	16
314	Accuracy of Rapid Influenza Diagnostic Tests. Annals of Internal Medicine, 2012, 156, 500.	3.9	408
315	Immunodiagnosis of Tuberculosis: State of the Art. Medical Principles and Practice, 2012, 21, 4-13.	2.4	42
316	Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax, 2012, 67, 62-70.	5.6	210
317	Point-of-care tuberculosis diagnosis: are we there yet?. Lancet Infectious Diseases, The, 2012, 12, 169-170.	9.1	20
318	As India grows, tuberculosis control must not be left behind. Lancet Infectious Diseases, The, 2012, 12, 263-265.	9.1	4
319	Tuberculosis control: business models for the private sector. Lancet Infectious Diseases, The, 2012, 12, 579-580.	9.1	26
320	How accurate are rapid influenza diagnostic tests?. Expert Review of Anti-Infective Therapy, 2012, 10, 615-617.	4.4	25
321	Which New Diagnostics for Tuberculosis, and When?. Journal of Infectious Diseases, 2012, 205, S191-S198.	4.0	55
322	Epidemiology of central lineâ€“associated bloodstream infections in Quebec intensive care units: A 6-year review. American Journal of Infection Control, 2012, 40, 221-226.	2.3	27
323	Predictive value of interferon-Î³ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 45-55.	9.1	441
324	Publicâ€“private mix in tuberculosis â€“ Authors' reply. Lancet Infectious Diseases, The, 2012, 12, 910-911.	9.1	0

#	Article	IF	Citations
325	Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis. Journal of Epidemiology and Global Health, 2012, 2, 39.	2.9	57
326	Research Questions and Priorities for Tuberculosis: A Survey of Published Systematic Reviews and Meta-Analyses. PLoS ONE, 2012, 7, e42479.	2.5	24
327	TB Screening in Canadian Health Care Workers Using Interferon-Gamma Release Assays. PLoS ONE, 2012, 7, e43014.	2.5	30
328	Point-of-Care Urine Tests for Smoking Status and Isoniazid Treatment Monitoring in Adult Patients. PLoS ONE, 2012, 7, e45913.	2.5	14
329	Interferon-Gamma Release Assays for Screening of Health Care Workers in Low Tuberculosis Incidence Settings: Dynamic Patterns and Interpretational Challenges. Canadian Respiratory Journal, 2012, 19, 81-83.	1.6	21
330	Bayesian Metaâ€Analysis of the Accuracy of a Test for Tuberculous Pleuritis in the Absence of a Gold Standard Reference. Biometrics, 2012, 68, 1285-1293.	1.4	85
331	Diagnosis of TB: state of the art. , 2012, , 124-143.		5
332	Surveillance Length and Validity of Benchmarks for Central Line-Associated Bloodstream Infection Incidence Rates in Intensive Care Units. PLoS ONE, 2012, 7, e36582.	2.5	4
333	Serological tests for the diagnosis of active tuberculosis: relevance for India. Indian Journal of Medical Research, 2012, 135, 695-702.	1.0	16
334	Point-of-care diagnostics for HIV and tuberculosis: landscape, pipeline, and unmet needs. Discovery Medicine, 2012, 13, 35-45.	0.5	49
335	Systematic Review and Meta-Analysis of Antigen Detection Tests for the Diagnosis of Tuberculosis. Vaccine Journal, 2011, 18, 1616-1627.	3.1	85
336	Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 132-140.	5.6	283
337	The BCG world atlas: a new, open-access resource for clinicians and researchers. Expert Review of Anti-Infective Therapy, 2011, 9, 559-561.	4.4	11
338	Developing a Tuberculosis Transmission Model That Accounts for Changes in Population Health. Medical Decision Making, 2011, 31, 53-68.	2.4	10
339	Surveillance Provinciale des Infections Nosocomiales (SPIN) Program: Implementation of a mandatory surveillance program for central line-associated bloodstream infections. American Journal of Infection Control, 2011, 39, 329-335.	2.3	19
340	Assays for drug resistant tuberculosis in high burden countries â€“ Authors' reply. Lancet Infectious Diseases, The, 2011, 11, 162.	9.1	1
341	Comparison of LED and Conventional Fluorescence Microscopy for Detection of Acid Fast Bacilli in a Low-Incidence Setting. PLoS ONE, 2011, 6, e22495.	2.5	39
342	Interferon-Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Individuals: A Systematic Review and Meta-Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 230-238.	2.1	260

#	Article	IF	Citations
343	Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Current Opinion in Rheumatology, 2011, 23, 377-384.	4.3	59
344	Predictive Value Of Igra And Tst In Indian Health-Care Workers: A Six-Year Follow Up Study. , 2011, , .		2
345	Translating tuberculosis research into global policies: the example of an international collaboration on diagnostics. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1283-1293.	1.2	11
346	Evaluation of light emitting diode-based fluorescence microscopy for the detection of mycobacteria in a tuberculosis-endemic region. International Journal of Tuberculosis and Lung Disease, 2011, 15, 483-488.	1.2	21
347	Widespread Abuse Of Serological Testing For Active TB In India: More Costly And Less Effective. , 2011, , .		0
348	Tuberculin skin test and QuantiFERONÂ® assay in young children investigated for tuberculosis in South Africa. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1176-1181.	1.2	38
349	Improving TB diagnosis: difference between knowing the path and walking the path. Expert Review of Molecular Diagnostics, 2011, 11, 241-244.	3.1	15
350	Guidelines on interferon-Î³ release assays for tuberculosis infection: concordance, discordance or confusion?. Clinical Microbiology and Infection, 2011, 17, 806-814.	6.0	135
351	Childhood Tuberculosis â€“ a new era. Paediatric Respiratory Reviews, 2011, 12, 1-2.	1.8	17
352	Immune-based diagnostics for TB in children: what is the evidence?. Paediatric Respiratory Reviews, 2011, 12, 9-15.	1.8	38
353	Predictive value of latent tuberculosis tests in Indian healthcare workers: a cohort study. European Respiratory Journal, 2011, 38, 1475-1477.	6.7	17
354	High prevalence of smoking among patients with suspected tuberculosis in South Africa. European Respiratory Journal, 2011, 38, 139-146.	6.7	57
355	Are interferon-Â release assays useful for diagnosing active tuberculosis in a high-burden setting?. European Respiratory Journal, 2011, 38, 649-656.	6.7	71
356	Interferon-Î³ Release Assays for Active Pulmonary Tuberculosis Diagnosis in Adults in Low- and Middle-Income Countries: Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2011, 204, S1120-S1129.	4.0	241
357	Comparative cost and performance of light-emitting diode microscopy in HIVâ€“tuberculosis-co-infected patients. European Respiratory Journal, 2011, 38, 1393-1397.	6.7	27
358	Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. European Respiratory Journal, 2011, 38, 1398-1405.	6.7	171
359	Systematic Review Of Interferon-Gamma Release Assays For Detection Of Latent Tuberculosis Infection In Patients With Immune-Mediated Inflammatory Disorders. , 2011, , .		0
360	Fading of Auramine-Stained Mycobacterial Smears and Implications for External Quality Assurance. Journal of Clinical Microbiology, 2011, 49, 2024-2026.	3.9	13

#	Article	IF	Citations
361	What Research Is Needed to Stop TB? Introducing the TB Research Movement. PLoS Medicine, 2011, 8, e1001135.	8.4	22
362	Serological Testing Versus Other Strategies for Diagnosis of Active Tuberculosis in India: A Cost-Effectiveness Analysis. PLoS Medicine, 2011, 8, e1001074.	8.4	63
363	Commercial Serological Tests for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis: An Updated Systematic Review and Meta-Analysis. PLoS Medicine, 2011, 8, e1001062.	8.4	209
364	The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. PLoS Medicine, 2011, 8, e1001012.	8.4	479
365	Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis. PLoS Medicine, 2011, 8, e1001063.	8.4	56
366	High Annual Risk of Tuberculosis Infection among Nursing Students in South India: A Cohort Study. PLoS ONE, 2011, 6, e26199.	2.5	32
367	Mismanagement of tuberculosis in India: Causes, consequences, and the way forward. Hypothesis (University of Toronto Dept of Medical Biophysics), 2011, 9, .	1.1	28
368	Tuberculosis control in India: time to get dangerously ambitious?. The National Medical Journal of India, 2011, 24, 65-8.	0.3	6
369	Protecting young healthcare trainees from tuberculosis: can we overcome apathy?. The National Medical Journal of India, 2011, 24, 198-200.	0.3	2
370	High Incidence of Hospital Admissions With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Among South African Health Care Workers. Annals of Internal Medicine, 2010, 153, 516.	3.9	151
371	New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Current Opinion in Pulmonary Medicine, 2010, 16, 1.	2.6	90
372	Spectrum of latent tuberculosis â€" existing tests cannot resolve the underlying phenotypes. Nature Reviews Microbiology, 2010, 8, 242-242.	28.6	76
373	Using MODS And/or TLA Techniques For Active Tuberculosis Diagnosis: A Systematic Review And Meta-Analysis. , 2010, , .		1
374	Tuberculosis in Children: New diagnostic Blood Tests. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, e111-e115.	1.9	5
375	Saudi guidelines for testing and treatment of latent tuberculosis infection. Annals of Saudi Medicine, 2010, 30, 38.	1.1	39
376	Expanding the Role of the Microscopic Observation Drug Susceptibility Assay in Tuberculosis and HIV Management. Clinical Infectious Diseases, 2010, 50, 997-999.	5.8	8
377	Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. European Respiratory Journal, 2010, 35, 27-33.	6.7	224
378	Treatment of Active Tuberculosis in HIVâ€Coinfected Patients: A Systematic Review and Metaâ€Analysis. Clinical Infectious Diseases, 2010, 50, 1288-1299.	5.8	158

#	Article	IF	Citations
379	Does Bleach Processing Increase the Accuracy of Sputum Smear Microscopy for Diagnosing Pulmonary Tuberculosis?. Journal of Clinical Microbiology, 2010, 48, 2433-2439.	3.9	51
380	Predicting outcomes and drug resistance with standardised treatment of active tuberculosis. European Respiratory Journal, 2010, 36, 870-877.	6.7	13
381	Evidence-based diagnosis of tuberculosis: Resources for the medical microbiologist. Indian Journal of Medical Microbiology, 2010, 28, 2-4.	0.8	1
382	Systematic Review Of Sensitivity Of Interferon-gamma Release Assays For Detection Of M. Tuberculosis Infection In HIV-infected Patients. , 2010, , .		2
383	Rapid diagnostics for influenza: what are the options?. Future Microbiology, 2010, 5, 1451-1455.	2.0	2
384	The Convergence of the Global Smoking, COPD, Tuberculosis, HIV, and Respiratory Infection Epidemics. Infectious Disease Clinics of North America, 2010, 24, 693-703.	5.1	38
385	Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet, The, 2010, 375, 1920-1937.	13.7	404
386	Biomarkers and diagnostics for tuberculosis â€“ Authors' reply. Lancet, The, 2010, 376, 1540.	13.7	0
387	Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2010, 10, 688-698.	9.1	116
388	Priorities for tuberculosis research: a systematic review. Lancet Infectious Diseases, The, 2010, 10, 886-892.	9.1	56
389	Tuberculosis Diagnosis â€" Time for a Game Change. New England Journal of Medicine, 2010, 363, 1070-1071.	27.0	164
390	Tuberculosis in children: New diagnostic blood tests. Paediatrics and Child Health, 2010, 15, 529-533.	0.6	15
391	Clinical Utility of a Commercial LAM-ELISA Assay for TB Diagnosis in HIV-Infected Patients Using Urine and Sputum Samples. PLoS ONE, 2010, 5, e9848.	2.5	117
392	Tuberculosis Infection among Young Nursing Trainees in South India. PLoS ONE, 2010, 5, e10408.	2.5	52
393	Recommendations on Interferon Gamma Release Assaysfor the Diagnosis of Latent Tuberculosis Infectionâ€"2010 Update. Canada Communicable Disease Report, 2010, 36, 1-22.	1.3	23
394	Saudi guidelines for testing and treatment of latent tuberculosis infection. Annals of Saudi Medicine, 2010, 30, 38-49.	1.1	2
395	Bacteriophage assays for rifampicin resistance detection in Mycobacterium tuberculosis: updated meta-analysis. International Journal of Tuberculosis and Lung Disease, 2010, 14, 941-51.	1.2	29
396	Assessing the impact of new diagnostics on tuberculosis control. International Journal of Tuberculosis and Lung Disease, 2010, 14, 1506-7.	1.2	10

#	Article	IF	Citations
397	A Pilot Study of Short-Duration Sputum Pretreatment Procedures for Optimizing Smear Microscopy for Tuberculosis. PLoS ONE, 2009, 4, e5626.	2.5	11
398	Within-Subject Variability of Interferon-g Assay Results for Tuberculosis and Boosting Effect of Tuberculin Skin Testing: A Systematic Review. PLoS ONE, 2009, 4, e8517.	2.5	171
399	Profile of adults seeking voluntary HIV testing and counseling in rural Central India: results from a hospital-based study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2009, 21, 294-300.	1.2	9
400	Light-emitting diode technologies for TB diagnosis: what is on the market?. Expert Review of Medical Devices, 2009, 6, 341-345.	2.8	41
401	Within-Subject Variability and Boosting of T-Cell Interferon-Î³ Responses after Tuberculin Skin Testing. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 49-58.	5.6	169
402	Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis. PLoS Medicine, 2009, 6, e1000150.	8.4	159
403	Effect of Duration and Intermittency of Rifampin on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis. PLoS Medicine, 2009, 6, e1000146.	8.4	169
404	Performance of Purified Antigens for Serodiagnosis of Pulmonary Tuberculosis: a Meta-Analysis. Vaccine Journal, 2009, 16, 260-276.	3.1	166
405	Interferon-Â release assays for the diagnosis of active tuberculosis: sensible or silly?. European Respiratory Journal, 2009, 33, 1250-1253.	6.7	66
406	Regions of Differences Encoded Antigens as Targets for Immunodiagnosis of Tuberculosis in Humans. Scandinavian Journal of Immunology, 2009, 70, 345-357.	2.7	31
407	Novel and Improved Technologies for Tuberculosis Diagnosis: Progress and Challenges. Clinics in Chest Medicine, 2009, 30, 701-716.	2.1	118
408	TB diagnostic tests: how do we figure out their costs?. Expert Review of Anti-Infective Therapy, 2009, 7, 723-733.	4.4	29
409	Comprehensive new resource for evidence-based TB diagnosis. Expert Review of Molecular Diagnostics, 2009, 9, 637-639.	3.1	14
410	T-cell interferon-Î³ release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Current Opinion in Pulmonary Medicine, 2009, 15, 188-200.	2.6	169
411	Quality and Reporting of Diagnostic Accuracy Studies in TB, HIV and Malaria: Evaluation Using QUADAS and STARD Standards. PLoS ONE, 2009, 4, e7753.	2.5	63
412	T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. International Journal of Tuberculosis and Lung Disease, 2009, 13, 84-92.	1.2	104
413	Diagnostics for tuberculosis: what new knowledge did we gain through The International Journal of Tuberculosis and Lung Disease in 2008?. International Journal of Tuberculosis and Lung Disease, 2009, 13, 691-7.	1.2	6
414	Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2008, 8, 359-368.	9.1	409

#	Article	IF	Citations
415	Comparison of QuantiFERON-TB Gold In-Tube to Tuberculin Skin Test for the Diagnosis of Active Tuberculosis (TB) in India - Preliminary Analysis. International Journal of Infectious Diseases, 2008, 12, e323-e324.	3.3	2
416	Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy. Expert Review of Respiratory Medicine, 2008, 2, 583-588.	2.5	46
417	GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. European Respiratory Journal, 2008, 32, 1165-1174.	6.7	306
418	Novel tests for diagnosing tuberculous pleural effusion: what works and what does not?. European Respiratory Journal, 2008, 31, 1098-1106.	6.7	137
419	Can Pleural Tuberculosis Be Diagnosed Using Interferon-Gamma Release Assays?. Respiration, 2008, 76, 128-130.	2.6	13
420	New Diagnostics for Latent and Active Tuberculosis: State of the Art and Future Prospects. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 560-568.	2.1	71
421	Rapid diagnosis of extrapulmonary tuberculosis using nucleic acid amplification tests: what is the evidence?. Future Microbiology, 2008, 3, 1-4.	2.0	30
422	Systematic Review: T-Cellâ€“based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update. Annals of Internal Medicine, 2008, 149, 177.	3.9	1,122
423	Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis. Annals of Internal Medicine, 2008, 149, 123.	3.9	151
424	Impact of Round-the-Clock, Rapid Oral Fluid HIV Testing of Women in Labor in Rural India. PLoS Medicine, 2008, 5, e92.	8.4	58
425	T-Cell Assays for Tuberculosis Infection: Deriving Cut-Offs for Conversions Using Reproducibility Data. PLoS ONE, 2008, 3, e1850.	2.5	89
426	Diagnosis of Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis: Current Standards and Challenges. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 169-172.	1.9	56
427	Evidence-Based Tuberculosis Diagnosis. PLoS Medicine, 2008, 5, e156.	8.4	72
428	Commercial Nucleic-Acid Amplification Tests for Diagnosis of Pulmonary Tuberculosis in Respiratory Specimens: Meta-Analysis and Meta-Regression. PLoS ONE, 2008, 3, e1536.	2.5	181
429	Improving the estimation of tuberculosis infection prevalence using T-cell-based assay and mixture models. International Journal of Tuberculosis and Lung Disease, 2008, 12, 895-902.	1.2	29
430	Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. International Journal of Tuberculosis and Lung Disease, 2008, 12, 498-505.	1.2	70
431	Serial Testing for Tuberculosis: Can We Make Sense of T Cell Assay Conversions and Reversions?. PLoS Medicine, 2007, 4, e208.	8.4	103
432	The New IGRA and the Old TST. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 529-531.	5.6	59

#	Article	IF	Citations
433	Editorial Commentary:Interferonâ€Î³ Release Assays: What Is Their Role in the Diagnosis of Active Tuberculosis?. Clinical Infectious Diseases, 2007, 44, 74-77.	5.8	87
434	Smoking and Tuberculosis: Infection, Disease, and Mortalityâ€"Reply. Archives of Internal Medicine, 2007, 167, 2009.	3.8	0
435	Risk of Tuberculosis From Exposure to Tobacco Smoke. Archives of Internal Medicine, 2007, 167, 335.	3.8	439
436	Recent advances in the diagnosis of childhood tuberculosis. Archives of Disease in Childhood, 2007, 92, 446-452.	1.9	137
437	Commercial serological tests for the diagnosis of tuberculosis: do they work?. Future Microbiology, 2007, 2, 355-359.	2.0	17
438	New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatric Respiratory Reviews, 2007, 8, 124-133.	1.8	108
439	Accuracy and reliability of physical signs in the diagnosis of pleural effusion. Respiratory Medicine, 2007, 101, 431-438.	2.9	55
440	The prognosis of latent tuberculosis: can disease be predicted?. Trends in Molecular Medicine, 2007, 13, 175-182.	6.7	173
441	Fluorescence microscopy for tuberculosis diagnosis â€“ Authors' reply. Lancet Infectious Diseases, The, 2007, 7, 239-240.	9.1	2
442	T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infectious Diseases, The, 2007, 7, 428-438.	9.1	167
443	Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research. Annals of Internal Medicine, 2007, 146, 340.	3.9	874
444	Lethal interaction: the colliding epidemics of tobacco and tuberculosis. Expert Review of Anti-Infective Therapy, 2007, 5, 385-391.	4.4	80
445	International Standards for Tuberculosis Care: revisiting the cornerstones of tuberculosis care and control. Expert Review of Anti-Infective Therapy, 2007, 5, 61-65.	4.4	20
446	Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. Expert Review of Anti-Infective Therapy, 2007, 5, 327-331.	4.4	123
447	A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. Postgraduate Medical Journal, 2007, 83, 705-712.	1.8	98
448	Evaluation of Diagnostic Accuracy, Feasibility and Client Preference for Rapid Oral Fluid-Based Diagnosis of HIV Infection in Rural India. PLoS ONE, 2007, 2, e367.	2.5	55
449	Prevalence of Abnormal Radiological Findings in Health Care Workers with Latent Tuberculosis Infection and Correlations with T Cell Immune Response. PLoS ONE, 2007, 2, e805.	2.5	36
450	Interferon-gamma release assays in children â€“ No better than tuberculin skin testing: Response to Ranganathan S etÂal.. Journal of Infection, 2007, 54, 414-415.	3.3	2

#	Article	IF	Citations
451	Interpretation of Mycobacterium tuberculosis antigen-specific IFN-Î³ release assays (T-SPOT.TB) and factors that may modulate test results. Journal of Infection, 2007, 55, 169-173.	3.3	56
452	The socio-cultural challenge in public health interventions: the case of tuberculosis in India. International Journal of Public Health, 2007, 52, 199-201.	2.3	7
453	Sensitivity of a Whole-Blood Interferon-Gamma Assay Among Patients with Pulmonary Tuberculosis and Variations in T-Cell Responses During Anti-Tuberculosis Treatment. Infection, 2007, 35, 98-103.	4.7	91
454	Comparison of a whole blood interferon-Î³ assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India. Journal of Infection, 2007, 54, 267-276.	3.3	155
455	Commercial Serological Antibody Detection Tests for the Diagnosis of Pulmonary Tuberculosis: A Systematic Review. PLoS Medicine, 2007, 4, e202.	8.4	189
456	Genetic diversity of pathogenic microorganisms and its medical and public health significance. Indian Journal of Medical Microbiology, 2007, 25, 2.	0.8	3
457	International standards for tuberculosis care: Relevance and implications for laboratory professionals. Indian Journal of Medical Microbiology, 2007, 25, 89.	0.8	5
458	New Tests for the Diagnosis of Latent Tuberculosis Infection. Annals of Internal Medicine, 2007, 147, 673.	3.9	1
459	Tuberculosis diagnostics trials: do they lack methodological rigor?. Expert Review of Molecular Diagnostics, 2006, 6, 509-514.	3.1	38
460	New tools and emerging technologies for the diagnosis of tuberculosis: Part II. Active tuberculosis and drug resistance. Expert Review of Molecular Diagnostics, 2006, 6, 423-432.	3.1	168
461	Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infectious Diseases, The, 2006, 6, 570-581.	9.1	649
462	Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infectious Diseases, The, 2006, 6, 664-674.	9.1	468
463	International Standards for Tuberculosis Care. Lancet Infectious Diseases, The, 2006, 6, 710-725.	9.1	308
464	Advances in the Diagnosis and Treatment of Tuberculosis. Proceedings of the American Thoracic Society, 2006, 3, 103-110.	3.5	150
465	Nosocomial Tuberculosis in India. Emerging Infectious Diseases, 2006, 12, 1311-1318.	4.3	50
466	Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. Journal of Occupational Medicine and Toxicology, 2006, 1, 7.	2.2	85
467	Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review. Tropical Medicine and International Health, 2006, 11, 789-799.	2.3	15
468	New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis. Expert Review of Molecular Diagnostics, 2006, 6, 413-422.	3.1	223

#	Article	IF	Citations
469	Serial Testing of Health Care Workers for Tuberculosis Using Interferon-Î³ Assay. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 349-355.	5.6	255
470	Tuberculosis among Health-Care Workers in Low- and Middle-Income Countries: A Systematic Review. PLoS Medicine, 2006, 3, e494.	8.4	422
471	Discordance between tuberculin skin test and interferon-gamma assays. International Journal of Tuberculosis and Lung Disease, 2006, 10, 942-3.	1.2	31
472	False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. International Journal of Tuberculosis and Lung Disease, 2006, 10, 1192-204.	1.2	424
473	Bacteriophage-based assays for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a meta-analysis. Journal of Infection, 2005, 51, 175-187.	3.3	81
474	In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression. BMC Microbiology, 2005, 5, 55.	3.3	149
475	Bacteriophage- based tests for the detection of Mycobacterium tuberculosis in clinical specimens: a systematic review and meta- analysis. BMC Infectious Diseases, 2005, 5, 59.	2.9	61
476	A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infectious Diseases, 2005, 5, 62.	2.9	204
477	Mycobacterium tuberculosis Infection in Health Care Workers in Rural India. JAMA - Journal of the American Medical Association, 2005, 293, 2746.	7.4	293
478	Tuberculosis, Vulnerability, and Access to Quality Care. JAMA - Journal of the American Medical Association, 2005, 293, 2790.	7.4	38
479	Interferon gamma assays for tuberculosis. Lancet Infectious Diseases, The, 2005, 5, 322-324.	9.1	35
480	Interferon gamma assays for tuberculosis. Lancet Infectious Diseases, The, 2005, 5, 325-327.	9.1	5
481	Simple clinical predictors of brain lesions in patients with impaired consciousness: a cross sectional study from a rural, tertiary hospital in central India. Clinical Neurology and Neurosurgery, 2005, 108, 25-31.	1.4	3
482	Interferon-Î³ Assays for Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 519-521.	5.6	59
483	Bacteriophage-based Tests for Tuberculosis. Indian Journal of Medical Microbiology, 2005, 23, 149.	0.8	5
484	Alternatives to the tuberculin skin test: Interferon-Î³ assays in the diagnosis of Mycobacterium Tuberculosis infection. Indian Journal of Medical Microbiology, 2005, 23, 151.	0.8	55
485	Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. BMC Infectious Diseases, 2004, 4, 6.	2.9	188
486	Lack of association of the HLA-DRB1 shared epitope with rheumatoid nodules: An individual patient data meta-analysis of 3,272 Caucasian patients with rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 753-762.	6.7	27

#	Article	IF	Citations
487	Particular HLAâ€“DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis and Rheumatism, 2004, 50, 3476-3484.	6.7	71
488	Nucleic acid amplification tests for diagnosis of tuberculous meningitis. Lancet Infectious Diseases, The, 2004, 4, 9.	9.1	0
489	Nucleic acid amplification tests for diagnosis of tuberculous meningitis. Lancet Infectious Diseases, The, 2004, 4, 11-12.	9.1	0
490	Interferon-Î³ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infectious Diseases, The, 2004, 4, 761-776.	9.1	876
491	Systematic reviews and meta-analyses: an illustrated, step-by-step guide. The National Medical Journal of India, 2004, 17, 86-95.	0.3	117
492	Systematic reviews of diagnostic test evaluations: What's behind the scenes?. ACP Journal Club, 2004, 141, A11-3.	0.1	26
493	The accuracy and reliability of nucleic acid amplification tests in the diagnosis of tuberculosis. The National Medical Journal of India, 2004, 17, 233-6.	0.3	16
494	Accuracy of perception and touch for detecting fever in adults: a hospital-based study from a rural, tertiary hospital in Central India. Tropical Medicine and International Health, 2003, 8, 408-414.	2.3	20
495	Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2003, 3, 633-643.	9.1	359
496	Metaâ€analysis of the Impact of HIV on the Infectiousness of Tuberculosis: Methodological Concerns. Clinical Infectious Diseases, 2002, 34, 1285-1287.	5.8	11
497	Clinical trials in India sponsored by the pharmaceutical industry: a proposal for reforms. The National Medical Journal of India, 2002, 15, 93-6.	0.3	0
498	Tuberculosis Diagnostics: State of the Art and Future Directions. , 0, , 361-378.		2
499	Economic costs of accessing tuberculosis (TB) diagnostic services in Malawi: an analysis of patient costs from a randomised controlled trial of computer-aided chest x-ray interpretation. Wellcome Open Research, 0, 6, 153.	1.8	2
500	Diagnosing at Point of Care in South India. Science and Technology Studies, 0, , 54-72.	0.7	9
501	Comment on: Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19). Journal of Antimicrobial Chemotherapy, 0, , .	3.0	3